News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

QR Pharma and University of California, Los Angeles (UCLA) Awarded $3 Million US Army Grant to Test Posiphen in Rat Models of Concussion and Blunt Head Trauma



10/10/2013 9:45:05 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BERWYN, Pa.--(BUSINESS WIRE)--QR Pharma, Inc. (QR) is a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment after acute brain injury like concussions, head trauma and stroke or in chronic degeneration like Alzheimer’s and Parkinson’s disease. QR and the University of California Los Angeles (UCLA) announce today they received a US Army grant in the amount of $3,000,000 to study Posiphen® in two models of traumatic brain injury (TBI).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES